Last reviewed · How we verify
NCT03363685
Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
trial in Spinal Metastases in 140 participants. Status unknown.
1 November 2022
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 140 |
| Start date | 1 November 2017 |
| Primary completion | 1 November 2022 |
| Estimated completion | 1 November 2022 |
| Sites | 1 location across China |
Conditions studied
- Spinal Metastases — all drugs for Spinal Metastases →
- Non-Small-Cell Lung Cancer Metastatic — all drugs for Non-Small-Cell Lung Cancer Metastatic →
Sponsor
Ruijin Hospital
Who can join
Adults 18 to 75, any sex, with Spinal Metastases or Non-Small-Cell Lung Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to learn whether our own made predictive algorithm can be used as a clinical practical decision support for patients with NSCLC spinal metastasis. The scoring system consists of the use of EGFR-TKI, KPS, Age, SCC, CA125 and smoking history. By predicting survival doctors could determine which patients are suitable for palliative therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis.
Zang S, He Q, Bao Q, Shen Y, et al · · 2019 · cited 9× · PMID 31028506 · DOI 10.1007/s10147-019-01452-8
Verify or expand the search:
- PubMed search for NCT03363685
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spinal Metastases
Currently open trials in the same condition.
- NCT06548061 — D20054;LITT for Spine Tumors · NA · recruiting
- NCT06244264 — The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis · NA · recruiting
- NCT06120426 — En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor · recruiting
- NCT05575323 — Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases · NA · recruiting
- NCT07429422 — SBRT Technique Implementation for Spinal Metastases Irradiation · NA · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03363685 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 8 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03363685.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing